Form 4: Fulgent Genetics COO Sells Shares for Tax Obligations

Fulgent Genetics' President and COO, Jian Xie, reported the sale of 1,199 common shares on August 27, 2025, to cover tax withholdings from RSU vesting.

Summary

• Jian Xie, President and COO of Fulgent Genetics, Inc., reported the sale of 1,199 shares of common stock.
• The transaction occurred on August 27, 2025, at a weighted-average price of $21.4847 per share.
• The sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted on February 26, 2024.
• Following this transaction, Mr. Xie directly owns 365,249 shares and indirectly owns 220,816 shares through The Hsieh Family Dynasty Trust.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes, which is neutral in sentiment. It does not indicate a change in management's confidence or the company's prospects.

Positives

• The sale was for a routine tax obligation, not a discretionary sale indicating a lack of confidence in the company.
• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating transparency and adherence to insider trading rules.

Negatives

• A reduction in direct beneficial ownership, albeit for a non-discretionary reason.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This filing, a routine insider transaction report, does not provide information relevant to broader industry trends or competitors.

Corporate Governance

Related Party Transactions

• Securities are indirectly held by The Hsieh Family Dynasty Trust, dated January 27, 2010, where Mr. Xie serves on the investment committee. Mr. Xie disclaims beneficial interest except for pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares sold for a routine tax obligation. The pre-planned nature under Rule 10b5-1(c) provides transparency.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an insider to cover tax obligations upon RSU vesting. This type of transaction is common and does not reflect a change in the insider's confidence in the company's future prospects. Given the small volume relative to total holdings and the tax-related nature, it provides no new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for either buying or selling.

Keywords

Fulgent Genetics, FLGT, Jian Xie, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan, Officer Transaction